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OBJECTIVES: Cancer patients who develop anemia are often
treated with erythropoietin-stimulating agents (ESAs), including
darbepoetin alfa (DA) or epoetin alfa (EA). This study compared
baseline characteristics, patterns of ESA use, costs, and dosing
among cancer patients as observed in a large managed care
claims database. METHODS: Medical and pharmacy claims
from a U.S. managed care database were used to identify 15,007
unique episodes of care (7238 with DA, 7769 with EA) in cancer
patients between January 2004 and 2006. Episodes included all
ESA claims with ≤42 day gap between claims, plus a duration of
clinical beneﬁt based on the median days between consecutive
doses for each product. The dose conversion ratio was calculated
as the mean weekly dose of EA to DA. Six sensitivity analyses
examined the robustness of ﬁndings to study methods. Costs
were determined from plan allowed amounts for ESA claims.
RESULTS: The mean (±SD) number of administrations per
episode was 3.7 (±4.1) for DA and 5.3 (±6.4) for EA. The mean
ESA episode duration was 55.5 (±64.7) days for DA and 59.2
(±59.2) days for EA and median time between consecutive claims
was 15 and 8, respectively. The estimated mean weekly dose was
105 (±56) mcg for DA and 34,242 (±28,174) U for EA. The cor-
responding dose ratio is 1 : 326. In the sensitivity analyses, mean
weekly doses were sensitive to the inclusion/exclusion of dura-
tion of clinical beneﬁt (dose ratio 1 : 326 vs. 1 : 237, respectively).
Patients receiving DA differed signiﬁcantly in baseline charac-
teristics compared to patients receiving EA. When DCB adjusted
costs were compared, the mean weekly cost of Aranesp was
lower than for Procrit. CONCLUSION: ESA use differed signif-
icantly between DA and EA. Adjustments for patterns of use are
necessary to appropriately compare the drugs and their costs.
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OBJECTIVES: Recent studies have established aging as a risk
factor of chemotherapy-induced neutropenia. Thus, the 2006
ASCO guideline added prophylactic use of CSF in older cancer
patients to its recommendations. Our study examined current
patterns of CSF use in outpatient settings in this population.
METHODS: We selected cancer patients with chemotherapy
from the 2001–2004 Medicare MarketScan data, a proprietary
dataset collecting Medicare and commercial claims for a group
of retirees with Medicare supplemental insurance. We deﬁned the
index date as the ﬁrst date of chemotherapy, followed patients
for 60 days, and classiﬁed high-risk patients as those whose
chemotherapy regimens had a greater than 40% risk of neu-
tropenia. We identiﬁed outpatient CSF use using HCPCS codes
and conducted logistic regression to examine factors associated
with CSF use; factors included age, gender, cancer types, risk
class, geographic regions, and the index year. A subgroup analy-
sis of the high-risk patients was also performed. RESULTS: We
found CSF use in 8.71% (5455 in 62,647) of the patients and
19.8% (754 in 3812) among high-risk patients. Compared with
patients in the age group 65–69, those in 75–79 and 80+ groups
were signiﬁcantly less likely to use CSF (OR = 0.83 CI:
0.76–0.90; OR = 0.73, CI: 0.66–0.79, respectively). High-risk
patients were more likely to use CSF (OR = 1.12, CI: 1.02–1.24),
so were those treated in more recent years. Compared with lung
cancer patients, breast cancer and lymphoma patients were 1.23
(CI: 1.15–1.41) and 1.81 (CI: 1.64–2.00) times more likely to
use CSF. Subgroup analysis showed that patients 75 and over
were signiﬁcantly less likely (OR = 0.83, CI: 0.70–0.99) to use
CSF than those under 75. CONCLUSION: The observed lower
rate in CSF use in the older age groups points to an unmet sup-
portive care need in a subgroup of patients who are more sus-
ceptible to neutropenia due to aging.
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OBJECTIVES: The payment of costly drugs is not included in
the DRG price within the context of the French case-mix based
hospital payment system (termed T2A) since 2005/01/01. These
drugs will be reimbursed on an additional cost basis after imple-
mentation of a “best practices” agreement (good practice refer-
ence guidelines drawn up by scientiﬁc societies and registration
agencies). The objective of this study was to assess the propor-
tion of off-label costly anticancer drug use in terms of reference
guidelines in oncology and the impact of their unreimbursement
on the hospital activity. METHODS: A 18-month retrospective
study (2005/01/01–2006/06/30) was performed in oncology
department. 11 costly anticancer drugs were eligible for the addi-
tional reimbursement. 8416 adult patient prescriptions (943
patients) including at least one of the eleven studied drugs were
analysed. For each prescription, the anticancer drug cost was cal-
culated. The analysis of use was performed by drug: conformity
to the ofﬁcial labelling (indication, dose, route of administration)
and level of scientiﬁc evidence. The off-label anticancer drug use
was discussed with prescribers in drug committee. RESULTS:
The proportion of off-label costly anticancer drug use is 32%
(2693/8416 prescriptions) and represents 29% (€2,020,373/
€6,877,879) of oncology overall drug budget. Among these pre-
scriptions, 43% (1153/2693 prescriptions) were supported by 
at least one randomized phase III trial and represent 59%
(€1,191,068/€2,020,373) of the oncology costly anticancer drug
induced cost. CONCLUSION: The reference guidelines should
lead towards the good use of these drugs and allow the sick funds
to control prescriptions. However, the ofﬁcial labelling of drugs
is unable to answer to all clinical situations and cannot be the
own references for costly anticancer drug reimbursement. The
anticancer drug prescriptions from therapeutic progress (justiﬁed
off label used) need to be reimbursed to maintain quality of
cancer care in French hospitals.
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OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. Women
between the ages 25–65 are invited by a personal letter and a 3
years screening interval has been applied. The screening rate
